{"id":"8b2f0020-5483-517d-a3da-a8c8a426ba7d","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-tt-bp-trial","predicate":"reduced_systolic_pressure_in_selected_trial","statement":"In hypertensive adults with MTHFR 677TT, the systolic treatment effect was 5.6±2.6 mmHg favoring riboflavin; the diastolic effect was not significant.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"fafed1ed-4353-527b-9b25-7619a6a4d7d6","mechanism_event_label":"A genotype-targeted trial found a systolic blood-pressure benefit while participants continued their usual medicines.","subject":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"object":{"id":"9eda1162-1823-5c43-8e7d-4f2e4858c353","slug":"blood-pressure","display_name":"Arterial blood pressure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"fafed1ed-4353-527b-9b25-7619a6a4d7d6","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-tt-bp-trial-event","event_type":"observed_intervention","label":"A genotype-targeted trial found a systolic blood-pressure benefit while participants continued their usual medicines.","description":"In hypertensive adults with MTHFR 677TT, the systolic treatment effect was 5.6±2.6 mmHg favoring riboflavin; the diastolic effect was not significant.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9fc32b1a-0f08-544c-a361-1c728203b6ec","slug":"mthfr","display_name":"Methylenetetrahydrofolate reductase / MTHFR","entity_type_key":"protein"},"role":"genotype_context","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"9eda1162-1823-5c43-8e7d-4f2e4858c353","slug":"blood-pressure","display_name":"Arterial blood pressure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"cross_nutrient","value_text":"Gene-cofactor clinical interaction; mechanism mediation was not demonstrated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"91 hypertensive adults with MTHFR 677TT and no overt cardiovascular disease; randomized trial on usual antihypertensive treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"1.6 mg/day riboflavin versus placebo for 16 weeks; experimental regimen.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Selected TT population; no proof of universal BP benefit, event reduction or a specific NO/methylation mechanism. Null diastolic endpoint retained.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Riboflavin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A genotype-targeted trial found a systolic blood-pressure benefit while participants continued their usual medicines.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b2-wilson2013] Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial (2013). https://pubmed.ncbi.nlm.nih.gov/23608654/ DOI: 10.1161/hypertensionaha.111.01047","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Human clinical setting","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"c1a80554-5ed2-54d9-b302-3f201b385f1e","evidence_kind":"source_excerpt","locator":"Lines 1527-1538","start_line":1527,"end_line":1538,"excerpt":"### b2-tt-bp-trial\nIn hypertensive adults with MTHFR 677TT, the systolic treatment effect was 5.6±2.6 mmHg favoring riboflavin; the diastolic effect was not significant.\nCondition category: machinery_impairment\nnutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A genotype-targeted trial found a systolic blood-pressure benefit while participants continued their usual medicines.\norganism: Homo sapiens\ntissue_or_cell_type: Human clinical setting\nexperimental_model: 91 hypertensive adults with MTHFR 677TT and no overt cardiovascular disease; randomized trial on usual antihypertensive treatment.\nlimitations: Selected TT population; no proof of universal BP benefit, event reduction or a specific NO/methylation mechanism. Null diastolic endpoint retained.\nexposure: 1.6 mg/day riboflavin versus placebo for 16 weeks; experimental regimen.\ncross_nutrient: Gene-cofactor clinical interaction; mechanism mediation was not demonstrated.\n[b2-wilson2013] Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial (2013). https://pubmed.ncbi.nlm.nih.gov/23608654/ DOI: 10.1161/hypertensionaha.111.01047","model_system":"91 hypertensive adults with MTHFR 677TT and no overt cardiovascular disease; randomized trial on usual antihypertensive treatment.","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b2-wilson2013] Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial (2013). https://pubmed.ncbi.nlm.nih.gov/23608654/ DOI: 10.1161/hypertensionaha.111.01047","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4f7c9578-82bf-5e2d-b5c4-72a79fb4f6af","stable_key":"import-548ab9d6-3a9b-5bed-879c-17d03813b636","title":"Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"680cb6bc8249877f2410f551807f10d390fdd719014137d7414ba3420e29228d","revision_id":"7a61e299-908d-5372-860b-99ed190f9d7a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}